{
    "root": "5384ef7c-88cc-4ab7-8eb7-627eba752f9d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Treprostinil"
    },
    "value": "20250213",
    "ingredients": [
        {
            "name": "TREPROSTINIL",
            "code": "RUM6K67ESG"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "METACRESOL",
            "code": "GGO4Y809LO"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        }
    ],
    "indications": "treprostinil injection prostacyclin mimetic indicated : • treatment pulmonary arterial hypertension ( pah ; group 1 ) diminish symptoms associated exercise . establishing effectiveness included patients nyha functional class ii-iv symptoms etiologies idiopathic heritable pah ( 58 % ) , pah associated congenital systemic-to-pulmonary shunts ( 23 % ) , pah associated connective tissue diseases ( 19 % ) . ( 1.1 ) • patients require transition epoprostenol , reduce rate deterioration . risks benefits carefully considered prior transition . ( 1.2 )",
    "contraindications": "pah group 1 patients nyha class ii-iv symptoms : • initial dose patients new prostacyclin infusion therapy : 1.25 ng/kg/min ; increase based response ( increments 1.25 ng/kg/min per week first 4 weeks treatment , later 2.5 ng/kg/min per week ) . avoid abrupt cessation . ( 2.2 , 2.4 ) • mild moderate hepatic insufficiency : decrease initial dose 0.625 ng/kg/min . severe hepatic insufficiency : performed . ( 2.5 ) transition epoprostenol : • increase treprostinil injection dose gradually epoprostenol dose decreased , based constant observation response . ( 2.7 ) : continuous subcutaneous infusion preferred mode . intravenous ( iv ) infusion subcutaneous infusion tolerated . ( 2.1 , 2.6 )",
    "warningsAndPrecautions": "treprostinil injection supplied 20-ml multi-dose vials sterile solutions water injection , individually packaged cartons . unopened vials treprostinil injection stable date indicated stored 25°c ( 77°f ) , excursions permitted 2-30°c ( 36-86°f ) . single vial treprostinil injection used 30 days initial introduction vial . treprostinil injection supplied : treprostinil injection concentration ndc 20 mg / 20 ml 1 mg/ ml 62332-514-20 50 mg / 20 ml 2.5 mg/ ml 62332-515-20 100 mg / 20 ml 5 mg/ ml 62332-516-20 200 mg / 20 ml 10 mg/ ml 62332-517-20",
    "adverseReactions": "none",
    "indications_original": "Treprostinil injection is a prostacyclin mimetic indicated for: • Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). (1.1) • Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. (1.2)",
    "contraindications_original": "PAH WHO Group 1 in patients with NYHA Class II-IV symptoms: • Initial dose for patients new to prostacyclin infusion therapy: 1.25 ng/kg/min; increase based on clinical response (increments of 1.25 ng/kg/min per week for the first 4 weeks of treatment, later 2.5 ng/kg/min per week). Avoid abrupt cessation. (2.2, 2.4) • Mild to moderate hepatic insufficiency: Decrease initial dose to 0.625 ng/kg/min. Severe hepatic insufficiency: No studies performed. (2.5) Transition from Epoprostenol: • Increase the Treprostinil injection dose gradually as the epoprostenol dose is decreased, based on constant observation of response. (2.7) Administration: Continuous subcutaneous infusion is the preferred mode. Use intravenous (IV) infusion if subcutaneous infusion is not tolerated. (2.1, 2.6)",
    "warningsAndPrecautions_original": "Treprostinil injection is supplied in 20-mL multi-dose vials as sterile solutions in water for injection, individually packaged in cartons. Unopened vials of Treprostinil injection are stable until the date indicated when stored at 25°C (77°F), with excursions permitted to 2-30°C (36-86°F). A single vial of Treprostinil injection should be used for no more than 30 days after the initial introduction into the vial.\n                     Treprostinil injection is supplied as:\n                  \n                  \n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              Treprostinil Injection\n                              \n                           \n                           \n                              Concentration\n                              \n                           \n                           \n                              NDC\n                              \n                           \n                        \n                        \n                           20 mg / 20 mL\n                           \n                           1 mg/ mL\n                           \n                           62332-514-20\n                           \n                        \n                        \n                           50 mg / 20 mL\n                           \n                           2.5 mg/ mL\n                           \n                           62332-515-20\n                           \n                        \n                        \n                           100 mg / 20 mL\n                           \n                           5 mg/ mL\n                           \n                           62332-516-20\n                           \n                        \n                        \n                           200 mg / 20 mL\n                           \n                           10 mg/ mL\n                           \n                           62332-517-20",
    "adverseReactions_original": "None"
}